Biomarker Discovery Outsourcing Services Market Report Scope and Overview:

The Biomarker Discovery Outsourcing Services Market was valued at USD 15.60 Billion in 2025 and is projected to reach USD 94.99 Billion by 2035, growing at a CAGR of 19.80% during the forecast period.

The Biomarker Discovery Outsourcing Services Market continues to expand as pharmaceutical and biotechnology sponsors increasingly route genomics, proteomics, and bioinformatics biomarker discovery work to specialized external partners rather than maintaining the full breadth of multi-omic platform capability in-house. Rising clinical trial reliance on patient stratification, companion diagnostic co-development, and surrogate endpoint validation is deepening demand for contract partners that combine wet-lab discovery capability with bioinformatics and statistical analysis expertise. Growing pipeline complexity across oncology, neurology, and autoimmune disease programs is further widening the addressable scope of outsourced biomarker work, as sponsors increasingly require partners capable of integrating genomic, proteomic, and transcriptomic data into a single translational biomarker strategy spanning early discovery through clinical validation.

⮞Thermo Fisher Scientific completed a large-scale Olink Explore HT proteomic analysis of approximately 5,500 samples for the Michael J. Fox Foundation's Parkinson's Precision Medicine Initiative in August 2026, illustrating the growing scale of outsourced proteomic biomarker discovery work supporting neurological disease research.

U.S. Biomarker Discovery Outsourcing Services Market Outlook

The U.S. Biomarker Discovery Outsourcing Services Market was valued at approximately USD 6.52 Billion in 2025 and is projected to reach USD 40.69 Billion by 2035, expanding at a CAGR of 20.10% over the forecast period.

Demand across the United States continued to be shaped by a dense concentration of innovator biopharmaceutical sponsors advancing precision oncology and immunology pipelines, sustained venture and public capital flow into early-stage biotechs without internal multi-omic platform capability, and growing regulatory emphasis on biomarker-driven patient selection in clinical trial design. Sponsors across oncology, neurology, and autoimmune programs continued favoring U.S.-based contract partners for proximity to clinical trial networks and regulatory infrastructure, while the expanding population of mid-sized biotechs without internal genomics or proteomics platforms continued to depend on outsourced partners for discovery-through-validation biomarker work. Growing sponsor interest in multi-cancer early detection and liquid biopsy biomarker platforms continued reinforcing demand for specialized contract capability across the country.

⮞Caris Life Sciences partnered with Everlywell in January 2026 to launch Caris Detect, a forthcoming whole-genome-sequencing-based multi-cancer early detection assay, extending biomarker-driven cancer screening to a broader U.S. consumer population.

By Biomarker Type: Surrogate Endpoint Biomarkers Lead, Predictive Biomarkers Grow Fastest

The Surrogate Endpoint Biomarkers segment dominated the Biomarker Discovery Outsourcing Services Market, supported by sustained regulatory acceptance of surrogate endpoints for accelerating clinical development timelines across oncology and chronic disease programs. Sponsors increasingly depend on specialized contract partners to validate and qualify surrogate markers against hard clinical endpoints, a process that requires statistical and translational expertise few developers maintain internally, particularly for smaller biotechs advancing a single late-stage asset.

The Predictive Biomarkers segment is growing fastest as precision medicine strategies increasingly require biomarkers capable of identifying which patients are most likely to respond to a given therapy ahead of treatment initiation. Expanding companion diagnostic co-development programs across targeted oncology and immunology pipelines are pulling investment toward predictive biomarker discovery capability, narrowing the gap with the surrogate endpoint segment over the forecast period.

By Service: Genomics Biomarker Services Dominate, Proteomics Biomarker Services Grow Fastest

The Genomics Biomarker Services segment dominated the Biomarker Discovery Outsourcing Services Market as next-generation sequencing and genotyping platforms remain the most mature and widely adopted biomarker discovery modality across sponsor pipelines. The breadth of established bioinformatics pipelines and reference databases built around genomic data continues to make genomics-focused contract partners the default first point of engagement for most discovery programs.

The Proteomics Biomarker Services segment is the fastest growing as high-throughput, multiplexed protein profiling platforms mature and become commercially accessible at the scale required for population-level biomarker studies. Rising sponsor interest in integrating proteomic signals alongside genomic data for a more complete translational biomarker picture is driving several contract partners to expand dedicated proteomics capacity.

By Therapeutic Area: Oncology Leads, Neurology Grows Fastest

The Oncology segment dominated the Biomarker Discovery Outsourcing Services Market, reflecting the sustained volume of targeted and immuno-oncology programs that depend on biomarker-driven patient selection and companion diagnostic co-development. Established tumor biobanking, patient-derived model, and translational assay infrastructure built around oncology work have made specialized contract partners the default choice for sponsors advancing precision cancer therapies.

The Neurology segment is the fastest growing as an expanding pipeline of disease-modifying therapies for Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions increasingly requires biomarker strategies capable of tracking disease progression and treatment response in the absence of fast-reading clinical endpoints, pushing sponsors toward specialized proteomic and imaging biomarker partners.

By End Use: Biotechnology Companies Dominate, Pharmaceutical Companies Grow Fastest

The Biotechnology Companies segment dominated the Biomarker Discovery Outsourcing Services Market as smaller, earlier-stage sponsors without internal multi-omic platform capability continue to rely most heavily on contract partners for discovery-through-validation biomarker work. Capital discipline among venture-backed biotechs continues reinforcing this outsourcing preference relative to building internal platform capability ahead of confirmed long-term pipeline need.

The Pharmaceutical Companies segment is the fastest growing as large sponsors increasingly supplement internal biomarker capability with specialized external partners for niche platforms, surge capacity during pivotal trial readouts, and access to proprietary bioinformatics tools not economical to replicate internally across every therapeutic area.

Regional Analysis

North America Biomarker Discovery Outsourcing Services Market Insights

North America dominated the Biomarker Discovery Outsourcing Services Market with the largest revenue share of approximately 47.20% in 2025, supported by the region's concentration of innovator biopharmaceutical sponsors, deep venture capital access for early-stage precision medicine companies, and an established base of CROs offering integrated genomics, proteomics, and bioinformatics discovery capability. The region's leading academic medical centers and biobanking infrastructure continue to make North America the preferred location for sponsors launching new translational biomarker programs, while ongoing consolidation among regional biomarker CROs is concentrating specialized platform capability among a smaller number of well-resourced partners.

The United States accounted for the substantial majority of regional revenue, anchored by sustained precision oncology and companion diagnostic program volume, strong public and private research funding, and a dense cluster of contract partners serving both coastal biotech hubs and established academic research corridors. Canada continued contributing a smaller but steady share of regional capacity, supported by specialized genomics and proteomics service providers serving cross-border sponsor programs and academic-industry research partnerships centered around major Canadian research hospitals.

Europe Biomarker Discovery Outsourcing Services Market Insights

Europe held a meaningful share of global revenue, supported by strong national investment in translational research infrastructure, an established base of academic-industry biomarker consortia, and a regulatory environment that has increasingly encouraged biomarker-driven clinical trial design across oncology and rare disease programs. Decades of accumulated genomics and proteomics research infrastructure across the region's leading research hospitals continue to attract sponsors seeking partners capable of handling complex translational biomarker studies.

Germany continued to lead regional demand at roughly 24.60% of European revenue, supported by its established academic and industrial genomics research base and a concentration of CROs offering integrated biomarker discovery capability, while the United Kingdom and Switzerland continued contributing significant proteomics and bioinformatics capacity to the regional market. France and the Nordic countries continued strengthening specialized niches in biobanking and population-scale genomics research supporting biomarker discovery programs.

Asia Pacific Biomarker Discovery Outsourcing Services Market Insights

Asia Pacific is advancing at the fastest pace, growing at a CAGR of approximately 22.70% from 2026 to 2035, driven by sustained capacity investment from regional contract research organizations, expanding clinical trial volume across the region, and rising sponsor confidence in the region's genomics and bioinformatics service quality following years of platform investment and talent development. Multinational sponsors are increasingly qualifying regional biomarker CROs as primary or secondary discovery partners, reflecting growing comfort with the data quality and documentation standards now in place across the region's leading providers.

China held a substantial share of regional revenue, supported by an expanding base of integrated CROs offering genomics, proteomics, and bioinformatics biomarker discovery capability, while India and South Korea continued strengthening their positions in cost-competitive genomics services and Japan maintained a specialized niche in high-value translational biomarker research. India's expanding sequencing capacity, in particular, continued attracting incremental investment from sponsors seeking cost-competitive discovery partners.

MEA and Latin America Biomarker Discovery Outsourcing Services Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by expanding clinical research infrastructure investment, rising local demand for precision medicine services, and gradually increasing interest from global sponsors in diversifying biomarker discovery capacity outside traditional research hubs.

Saudi Arabia led Middle East and Africa demand, supported by the country's genomics and precision medicine investment initiatives, while Brazil led Latin America, benefiting from an established clinical research base and growing government support for translational biomarker research programs.

Market Dynamics

Growth Drivers: Rising Precision Medicine Adoption and Expanding Multi-Omic Outsourcing

The industry is driven by rising adoption of precision medicine strategies across oncology, neurology, and immunology pipelines, and the growing preference among both innovator and emerging sponsors to route genomics, proteomics, and bioinformatics biomarker discovery work to specialized contract partners rather than building internal multi-omic platform capability for programs with uncertain long-term volume requirements. Mid-sized and emerging biopharmaceutical companies in particular continue to view outsourced biomarker discovery as a way to preserve capital for clinical development while accessing platform capability that would otherwise take years to establish internally. The growing number of regulatory approvals tied to biomarker-defined patient populations continues reinforcing sponsor willingness to invest in dedicated discovery and validation programs early in development.

Rising demand for companion diagnostic co-development continues supporting capacity investment, as precision oncology and immunology sponsors increasingly require biomarker partners capable of taking a candidate biomarker from discovery through regulatory-grade validation. The expanding pipeline of targeted therapies requiring patient stratification continues to reinforce this dynamic, pushing leading biomarker CROs to add dedicated proteomics and bioinformatics capacity well ahead of confirmed long-term demand. Growing payer interest in biomarker-guided treatment selection is further reinforcing this trend across both oncology and chronic disease categories.

Restraints: Platform Standardization Gaps and Data Integration Complexity

Persistent gaps in cross-platform standardization, particularly across proteomics assay technologies, continue posing a restraint, with sponsors often facing difficulty comparing biomarker data generated on different platforms across multi-site or multi-year clinical programs. Smaller sponsors in particular can find themselves locked into a single contract partner's proprietary platform, complicating future data integration or partner transitions when a program advances to a different development stage.

Data integration complexity across genomic, proteomic, and clinical datasets continues posing execution risk, particularly for multi-omic biomarker programs where incomplete harmonization of data formats and quality standards can delay regulatory submission timelines. These challenges are often compounded when a program moves between multiple contract partners across its development lifecycle, each generating data in a different format, requiring additional bioinformatics work simply to reconcile prior results.

Opportunities: Companion Diagnostic Expansion and Emerging Market Capacity Growth

Rising complexity in companion diagnostic co-development, including multi-marker and multi-omic assay requirements, represents a significant opportunity for contract partners able to combine discovery-stage biomarker science with regulatory-grade validation capability across multiple jurisdictions simultaneously. Sponsors lacking this combined capability internally are increasingly turning to specialized biomarker CROs to remain competitive in precision medicine development, particularly as regulators increasingly expect biomarker strategies to be defined earlier in the development lifecycle.

Expanding capacity investment across Asia Pacific and emerging research hubs offers a second substantial opportunity, as sponsors seeking to diversify biomarker discovery capacity beyond traditional research regions increasingly qualify additional contract partners to access cost-competitive genomics and bioinformatics talent while reducing geographic concentration risk. This diversification trend is creating room for a broader set of regional biomarker CROs to win qualification from multinational sponsors.

Biomarker Discovery Outsourcing Services Market key players are:

• Almac Group

• Crown Bioscience (Adicon Holdings)

• Evotec SE

• Frontage Laboratories, Inc.

• Excelra

• Parexel International Corporation

• Bio-Rad Laboratories, Inc.

• Sino Biological Inc.

• Emery Pharma

• RayBiotech, Inc.

• REPROCELL Inc.

• Selvita S.A.

• Svar Life Science AB

• Sapient Bioanalytics

• Caris Life Sciences

• Illumina, Inc.

• 10x Genomics, Inc.

• Standard BioTools Inc.

• SOPHiA GENETICS SA

• Precision for Medicine, Inc.

Biomarker Discovery Outsourcing Services Market Report Scope: